Levetiracetam Noridem (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action reduces neuronal hyper‑excitability and stabilizes synaptic transmission, helping to prevent the spread of seizure activity across the brain.

The dose of Levetiracetam Noridem is individualized by the prescribing clinician based on the patient’s age, weight, renal function, seizure type and clinical response. No fixed dosing regimen is provided here; the prescriber sets the appropriate regimen.

Levetiracetam’s pregnancy category is listed as unknown, meaning the potential risks are not fully established. It should be used only if the expected benefit justifies the potential risk to the fetus. Breastfeeding decisions should also consider the drug’s presence in milk and the infant’s condition.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Levetiracetam has a distinct mechanism (SV2A binding) and a relatively favorable interaction profile compared with many enzyme‑inducing antiepileptics. It does not require routine therapeutic drug monitoring, but clinicians still consider efficacy, tolerability, and patient‑specific factors when choosing between levetiracetam and alternatives such as carbamazepine or valproate.

The product should be stored at 2‑8 °C, kept refrigerated, protected from light, and never frozen or shaken. Once removed from controlled storage, it should be used within the time frame specified by the manufacturer and handled using aseptic technique to maintain sterility.

Levetiracetam Noridem is given by intravenous infusion. The solution is diluted according to the prescribing information and infused over a period determined by the clinician, typically ranging from a rapid bolus to a slower infusion depending on the clinical situation.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, blood dyscrasias, emergence of suicidal thoughts or severe depression, and respiratory depression when combined with other central nervous system depressants. Prompt medical attention is required if any of these occur.

Patients with known hypersensitivity to levetiracetam or any component of the formulation should avoid its use. Caution is also advised for individuals with severe renal impairment, uncontrolled psychiatric conditions, or those receiving live vaccines, as these situations may increase the risk of adverse outcomes.